Topic: infectious disease
Preliminary results from a trio of phase 1 studies showed promise for the Zika vaccine Sanofi had previously left behind.
On the heels of a safety warning, the Philippines' FDA ordered Sanofi to pull its Dengvaxia shot from the market.
The Philippines halted its dengue vaccination program after Sanofi flagged serious risks for recipients who'd never been infected with the virus.
With financial support from BARDA, Takeda's purified, inactivated, alum-adjuvanted Zika vaccine has entered human testing.
A study published in Pediatrics showed that protection of Merck's Gardasil lasts over 10 years.
Immunovaccine and Leidos are working together to determine the most promising malaria vaccine formulations.
Merck and GSK are coping with hepatitis A vaccine shortages as the U.S. is experiencing deadly outbreaks.
Now that Prostvac has failed as a stand-alone therapy, Bavarian Nordic's MVA-BN RSV vaccine is now extra-important.
Takeda's dengue vaccine induced sustained antibody responses in children, topline phase 2 data showed.
Aviragen and Vaxart merged into one company aimed at developing oral vaccines against flu, norovirus and RSV.